The importance of the tumor suppressor activity of BCL6 is underlined by the fact that lymphomas with double translocation of MYC and BCL2 are among those with the worst prognosis.99 From the therapeutic standpoint, targeting BCL6 is lethal to lymphoma cells, but can also result in induction of target genes like BCL2 resulting in a process described as “oncogene switching.” Along these lines combination of BCL6 and BCL2 inhibitors is highly synergistic in killing lymphoma cells.100. The gene discussed is BCL2; the disease is lymphoma.